Clonidine: Difference between revisions
(Redirected page to Clonidine Toxicity) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
# | ==Administration== | ||
*Type: [[Antihypertensive]], Central alpha-2 agonist | |||
*Dosage Forms: Tablets (0.1mg, 0.2mg, 0.3mg); Transdermal patches; Injectable | |||
*Routes of Administration: PO, IV, Transdermal | |||
*Common Trade Names: Catapres, Duraclon | |||
==Adult Dosing== | |||
===General=== | |||
*Hypertension: 0.1mg PO BID, titrate as needed | |||
*Acute hypertension: 0.1-0.2mg PO, may repeat hourly (max 0.6mg) | |||
==Pediatric Dosing== | |||
===General=== | |||
*5-10mcg/kg/day PO divided q8-12h | |||
==Special Populations== | |||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | |||
*[[Lactation risk categories|Lactation risk]]: Enters breast milk, use caution | |||
===Renal Dosing=== | |||
*Adjust dose; reduce in renal impairment | |||
===Hepatic Dosing=== | |||
*Use caution in hepatic impairment | |||
==Contraindications== | |||
*Allergy to class/drug | |||
==Adverse Drug Reactions== | |||
===Serious=== | |||
*Rebound hypertension with abrupt discontinuation | |||
*Bradycardia | |||
*Hypotension | |||
===Common=== | |||
*Dry mouth | |||
*Drowsiness/sedation | |||
*Constipation | |||
*Dizziness | |||
==Pharmacology== | |||
*Onset of action: 30-60 minutes (PO) | |||
*Half-life: 12-16 hours | |||
*Metabolism: Hepatic (50%) | |||
*Excretion: Renal (40-60% unchanged) | |||
==Mechanism of Action== | |||
*Stimulates alpha-2 adrenergic receptors in the brainstem, reducing sympathetic outflow from the CNS | |||
*Decreases peripheral resistance, heart rate, and blood pressure | |||
==Indications by Condition== | |||
{{#ask:[[Has DrugName::Clonidine]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | |||
*[[Clonidine toxicity]] | |||
*[[Opioid withdrawal]] | |||
*[[Hypertensive emergency]] | |||
*[[Antihypertensives]] | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | |||
[[Category:Cardiology]] | |||
Latest revision as of 21:57, 20 March 2026
Administration
- Type: Antihypertensive, Central alpha-2 agonist
- Dosage Forms: Tablets (0.1mg, 0.2mg, 0.3mg); Transdermal patches; Injectable
- Routes of Administration: PO, IV, Transdermal
- Common Trade Names: Catapres, Duraclon
Adult Dosing
General
- Hypertension: 0.1mg PO BID, titrate as needed
- Acute hypertension: 0.1-0.2mg PO, may repeat hourly (max 0.6mg)
Pediatric Dosing
General
- 5-10mcg/kg/day PO divided q8-12h
Special Populations
- Pregnancy Rating: C
- Lactation risk: Enters breast milk, use caution
Renal Dosing
- Adjust dose; reduce in renal impairment
Hepatic Dosing
- Use caution in hepatic impairment
Contraindications
- Allergy to class/drug
Adverse Drug Reactions
Serious
- Rebound hypertension with abrupt discontinuation
- Bradycardia
- Hypotension
Common
- Dry mouth
- Drowsiness/sedation
- Constipation
- Dizziness
Pharmacology
- Onset of action: 30-60 minutes (PO)
- Half-life: 12-16 hours
- Metabolism: Hepatic (50%)
- Excretion: Renal (40-60% unchanged)
Mechanism of Action
- Stimulates alpha-2 adrenergic receptors in the brainstem, reducing sympathetic outflow from the CNS
- Decreases peripheral resistance, heart rate, and blood pressure
Indications by Condition
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Opioid withdrawal | 0.1mg q60min PRN | Suppress sympathetic hyperactivity during withdrawal | PO | Adult |
| Opioid withdrawal (peds) | 0.1mg PO q60min PRN (or 5mcg/kg if SBP >90) | Suppress sympathetic hyperactivity | PO | Adult |
